UNITED STATES SECURITIES AND EXCHANGE COMMISSION March 7, 2019

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Recro Pharma, Inc.

File No. 1-36329 -- CF# 37224

Recro Pharma, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on February 19, 2019.

Based on representations by Recro Pharma, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.26 through August 11, 2020

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary